NRP1 Presented in trans to the Endothelium Arrests VEGFR2 Endocytosis, Preventing Angiogenic Signaling and Tumor Initiation

Sina Koch, Laurens A. van Meeteren, Eric Morin, +7

Developmental Cell

AngiogenesisMedicineEndothelial DysfunctionTumor InitiationVascular Biology +10

Gefitinib Induces Epidermal Growth Factor Receptor Dimers Which Alters the Interaction Characteristics with 125I-EGF

Hanna Björkelund, Lars Gedda, Pavel Bárta, +2

PLoS ONE

Comparing the Epidermal Growth Factor Interaction with Four Different Cell Lines: Intriguing Effects Imply Strong Dependency of Cellular Context

Hanna Björkelund, Lars Gedda, Karl Andersson

PLoS ONE

CD14 Mediates Binding of High Doses of LPS but Is Dispensable for TNF-<b><i>α</i></b>Production

Kinga Borzęcka, Agnieszka Płóciennikowska, Hanna Björkelund, +2

Mediators of Inflammation

ImmunologyImmune RegulationImmunologic MechanismCd4 T Cell ResponsesInnate Immunity +20

Deciphering complex protein interaction kinetics using Interaction Map

Danièle Altschuh, Hanna Björkelund, John Strandgård, +3

Biochemical and Biophysical Research Communications

Interaction MapEngineeringInteractomicsProtein FoldingComputational Biology +4

Multivalent Fcγ-receptor engagement by a hexameric Fc-fusion protein triggers Fcγ-receptor internalisation and modulation of Fcγ-receptor functions

Omar Qureshi, Tania F. Rowley, Fabian Junker, +20

Scientific Reports

Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach

Hanna Björkelund, Lars Gedda, Magnus Malmqvist, +1

Molecular and Clinical Oncology

Selection and <i>in vitro</i> characterization of human CD44v6‐binding antibody fragments

Johan Nilvebrant, Gamze Kuku, Hanna Björkelund, +1

Biotechnology and Applied Biochemistry

ImmunologyImmunoeditingImmunodominanceFab FragmentsAntigen Processing +19

The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B—a prerequisite for clinical development

Elisabeth J. M. Huijbers, Julia Femel, Karl Andersson, +3

Vaccine

VaccinationOncologyMedicineImmunologyTherapeutic Vaccine +11

Avidity characterization of genetically engineered T-cells with novel and established approaches

Victoria Hillerdal, Vanessa F. Boura, Hanna Björkelund, +2

BMC Immunology